Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ Xywav — Number of patents, paragraph IV certification notice filed

Similar metrics at other companies

Incyte logo
INCYJAKAVI — Total revenues
$105.6M+14.7%
Incyte logo
INCYJAKAVI — Royalties payable on net sales
$96.6M+12.6%
Incyte logo
INCYJAKAVI Royalty Revenues — Total revenues
$105.56M+14.6%
Incyte logo
INCYJAKAVI — Royalty payments on future global net sales (as a percent)
14%0.0pp
Exelixis logo
EXELProducts derived from cabozantinib — Number of products that entered in the commercial marketplace
20.0%
Biogen logo
BIIBGAZYVA — After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date
39%0.0pp

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept jazz:NumberOfPatentsParagraphIVCertificationNoticeFiled.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's xywav — number of patents, paragraph iv certification notice filed.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's xywav — number of patents, paragraph IV certification notice filed?
Jazz Pharmaceuticals (JAZZ) reported xywav — number of patents, paragraph IV certification notice filed of 15 in Q1 2026.
What does xywav — number of patents, paragraph IV certification notice filed mean?
The number of legal challenges filed by generic competitors against the patents protecting a specific drug.
How do you interpret xywav — number of patents, paragraph IV certification notice filed?
An increase indicates heightened legal pressure and a higher risk of imminent generic entry, which could negatively impact long-term revenue sustainability.
How does xywav — number of patents, paragraph IV certification notice filed compare across companies?
Peers in the specialty pharmaceutical space report this as part of their litigation disclosures and 10-K risk factors regarding patent cliffs.